---
figid: PMC6097934__nihms969408f5
figlink: /pmc/articles/PMC6097934/figure/F5/
number: F5
caption: Proposed mechanism of action of PAC-1 combination therapy with clinically
  approved kinase inhibitors examined in this work. Shown kinase inhibitors target
  key oncogenic driver kinases, leading to transient inhibition of signaling through
  MEK. Of critical importance is the ability of PAC-1 treatment to induce cleavage
  of MEK kinases. This MEK cleavage, in conjunction with upstream pathway inhibition,
  potently abolishes ERK phosphorylation and hinders pro-survival and proliferation
  signaling.
pmcid: PMC6097934
papertitle: Overcoming Resistance to Targeted Anticancer Therapies through Small-Molecule
  Mediated MEK Degradation.
reftext: Jessie Peh, et al. Cell Chem Biol. 2018 Aug 16;25(8):996-1005.e4.
pmc_ranked_result_index: '78338'
pathway_score: 0.946316
filename: nihms969408f5.jpg
figtitle: Action of PAC-1 combination therapy with clinically approved kinase inhibitors
  examined in this work
year: '2018'
organisms:
- Homo sapiens
ndex: ed4fa750-def7-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6097934__nihms969408f5.html
  '@type': Dataset
  description: Proposed mechanism of action of PAC-1 combination therapy with clinically
    approved kinase inhibitors examined in this work. Shown kinase inhibitors target
    key oncogenic driver kinases, leading to transient inhibition of signaling through
    MEK. Of critical importance is the ability of PAC-1 treatment to induce cleavage
    of MEK kinases. This MEK cleavage, in conjunction with upstream pathway inhibition,
    potently abolishes ERK phosphorylation and hinders pro-survival and proliferation
    signaling.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - MAPK1
  - BRAF
  - MAPK3
  - NRAS
  - RAF1
  - HRAS
  - KRAS
  - MAP2K2
  - ARAF
  - DUSP2
  - MAP2K1
  - Osimertinib
  - Imatinib
  - Vemurafenib
  - Zn2
  - Zn2+
  - PAC
genes:
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: BRAF
  symbol: BRAF
  source: hgnc_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: PAC-1
  symbol: PAC-1
  source: hgnc_alias_symbol
  hgnc_symbol: DUSP2
  entrez: '1844'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
chemicals:
- word: Osimertinib
  source: ''
  identifier: ''
- word: Imatinib
  source: MESH
  identifier: C097613
- word: Vemurafenib
  source: MESH
  identifier: C551177
- word: Zn2
  source: MESH
  identifier: D015032
- word: Zn2+
  source: MESH
  identifier: D015032
- word: PAC
  source: MESH
  identifier: C054549
diseases: []
figid_alias: PMC6097934__F5
redirect_from: /figures/PMC6097934__F5
figtype: Figure
---
